Protocol Ledger

NCT06948448 · Phase II · RECRUITING

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced C

Interventional Phase II clinical trial protocol NCT06948448 sponsored by Ono Pharmaceutical Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-18 Enrollment: 144 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06948448
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)144 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06948448
Protocol FieldVerified Registry Value
NCT IdentifierNCT06948448
Consolidated Lead SponsorOno Pharmaceutical Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment144 participants (ESTIMATED)
Registered Start Date2025-11-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI